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Summary Background ME-143, a second-generation
tumor-specific NADH oxidase inhibitor, is broadly active
against human cancers in vitro and in vivo. This first-in-
human dose-escalation study evaluated the dose-limiting
toxicities (DLTs), pharmacokinetics, safety, tolerability,
and preliminary anti-tumor activity of ME-143 in patients
with advanced solid tumors. Methods Patients with ad-
vanced solid tumors were treated in a 3+3 escalation design.
ME-143 was administered via intravenous infusion on days
1, 8, and 15 of the first 28-daycycle, and weekly thereafter;
the final cohort received twice-weekly treatment. Samples
for pharmacokinetic analysis were collected during cycle 1.
Treatment continued until disease progression or unacceptable
toxicity. Results Eighteen patients were treated: 2.5 mg/kg
(n=3); 5 mg/kg (n=3); 10 mg/kg (n=3); 20 mg/kg (n=6);
20 mg/kg twice-weekly (n=3). There were no DLTs observed.
Nearly all treatment-related toxicities were grade 1/2, specifically
(all grades) nausea (22 %) and fatigue (17 %). Two patients
experienced infusion reactions at the 20mg/kg dose level, one of
which was grade 4. Stable disease was documented in three
patients with colorectal cancer, cholangiocarcinoma, and anal
cancer. Pharmacokinetic exposures were linear and dose-
dependent, with a half-life of approximately 5 h. Conclusions
ME-143 was well-tolerated when administered intravenously at
the maximally administered/recommended phase 2 dose of
20 mg/kg once weekly to patients with advanced solid tumors.
Though limited clinical activitywas observedwithmonotherapy,
inhibitors of tumor-specific NADH oxidase such as ME-143
may derive their greatest benefit in combination with cytotoxic
chemotherapy.
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Introduction
Isoflavone derivatives are a class of small molecule inhibitors
with unique anti-cancer properties. These compounds selec-
tively bind to a tumor-specific, splice variant form of NADH
oxidase (tNOX) as compared with constitutively expressed
NADH oxidase in normal cells. In tumor cells, the binding of
tNOX shifts the ceramide-S1P equilibrium resulting in prompt
apoptosis via pleotropic caspase activation [1]. Phenoxodiol is
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the most well studied molecule in this class having been
administered to over 200 patients in both oral and intrave-
nous formulations [MEI Pharma, Inc, data on file]. Overall
phenoxodiol is well-tolerated with limited side effects [2].
No dose-limiting toxicities were observed when given in-
travenously, however diarrhea is limiting with the oral
administration [2]. In a phase II study of intravenous
phenoxodiol in combination with cisplatin or paclitaxel
for women with epithelial ovarian, fallopian tube, or pri-
mary peritoneal cancers, three of 16 (19 %) platinum-
refractory ovarian cancer patients had a partial response
with 9 (56 %) patients achieving stable disease [3]. A
subsequent phase III study evaluating an oral formulation
of phenoxodiol in combination with carboplatin in patients
with platinum-refractory ovarian cancer did not meet its
primary endpoint of improved progression-free survival
(clinicaltrials.gov, NCT00382811; MEI Pharma, Inc, data
on file); however, these results may be confounded by
bioavailability issues with the oral formulation.
ME-143 is a synthetic second-generation tNOX inhibi-
tor. It is an analogue of the first generation compounds
phenoxodiol and triphendiol, but with significantly greater
potency with in vitro IC50’s generally <1 μM. After
binding to tNOX, ME-143 has been shown in preclinical
studies to cause tumor cell-specific inhibition of plasma
membrane electron transport (pMET), inhibition of AKT
phosphorylation, inactivation of the x-linked inhibitor of
apoptosis protein (XIAP), and induction of caspase-
dependent apoptosis through both extrinsic and intrinsic
pathways [4, 5]. Dose dependent inhibition of human
tumor xenograft growth was seen in mice, with a growth
inhibition plateau between 50 – 100 mg/kg [MEI Pharma
Inc, data on file]. A dose of 100 mg/kg in mice with an
AUC of ~20,000 ng*h/mL correlates to a human dose and
potential target of approximately 18 mg/kg. The only
significant laboratory findings in rats and dogs were dose
dependent reduction in urinary sperm counts, and atrophy
of the testis and epididymis (noted in the rat studies). The
defined no observed adverse effect level (NOAEL) was
8 mg/kg. While there was no defined severely toxic dose
(STD), including the highest dose level of 140 mg/kg, the
starting dose of ME-143 in this study was 2.5 mg/kg,
approximately 10 % of the maximal dose delivered to
animals. A weekly IV dosing schedule was selected based
on the evidence of activity generated in phase II studies of
phenoxodiol in ovarian cancer [3].
The primary objectives of this first-in-human phase
1 dose escalation trial were to determine the tolerability,
adverse event profile, and dose-limiting toxicities (DLTs)
of ME-143. Secondary objectives included assessments of
the pharmacokinetic (PK) profile and preliminary anti-
tumor activity of ME-143 observed in patients with re-
fractory solid tumors.
Patients and methods
This phase 1, open-label, non-randomized, dose-escalation
(Clinicaltrials.gov, NCT01401868) was approved by the
institutional review boards of both participating sites: Sarah
Cannon Research Institute/Tennessee Oncology, PLLC
(Nashville, TN), and University of Oklahoma (Oklahoma
City, OK). All patients provided written informed consent.
The study was conducted in accordance with all applicable
regulatory guidelines and under the guidance of the Decla-
ration of Helsinki [6].
Patient selection
Adult patients with advanced cancer for which there were no
standard therapeutic alternatives and Eastern Cooperative
Oncology (ECOG) performance status of 0 or 1 were in-
cluded. Other eligibility criteria included: life expectancy
of ≥12 weeks; ≥4 weeks since last anti-cancer therapy and
21 days since last radiotherapy, immunotherapy or surgery
(≥14 days for limited palliative radiotherapy). Adequate bone
marrow, hepatic, and renal function for study inclusion were
defined as: absolute neutrophil count (ANC) >1.5×109/L;
platelets >100×109/L; hemoglobin >9 g/dL; bilirubin ≤1.5
times the institutional upper limit of normal (ULN); aspartate
transaminase (AST) and alanine transaminase (ALT) ≤2.5x
ULN, or <5x ULN for patients with liver metastases; creati-
nine ≤1.5 x ULN. Women were required to have a follicle
stimulating hormone (FSH) level within normal limits and
those of child-bearing potential must have had a negative
serum pregnancy test. Men were required to have a detectable
level of testosterone.
Patients with active central nervous system (CNS) metas-
tases were excluded; however, those with treated CNS metas-
tases could be enrolled after approval of the medical monitor.
Additional exclusion criteria were: uncontrolled infection or
systemic disease; cardiac disease not well controlled or myo-
cardial infarction within the last 12 months; average QTc from
triplicate electrocardiograms (ECGs) ≥470 msec; hypersensi-
tivity to ME-143 or components; human immunodeficiency
virus (HIV) or Hepatitis B or C (active, previously treated, or
both); history of solid organ transplant; psychiatric, social, or
geographic situations precluding study participation.
Treatment and dose modifications
Five cohorts were planned (2.5 mg/kg; 5 mg/kg; 10 mg/kg;
20 mg/kg; MTD or 20 mg/kg twice weekly). Four cohorts
were initially planned for once weekly administration of
ME-143 at 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 20 mg/kg.
The protocol was amended (12/21/2011) to enroll a fifth
cohort with twice-weekly dosing once the weekly cohorts
were completed.
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ME-143 was formulated with Captisol™ in water, with
each 10 mL vial containing 35 mg/mL of ME-143 and
300 mg/mL of Captisol (ratio approximately 1:8.6), and
was diluted with saline prior to administration as an intra-
venous (IV) infusion over 30 min on days 1, 8, and 15 of
cycle 1 (28 days). In subsequent cycles, ME-143 was ad-
ministered weekly with no week of rest. In the twice-weekly
dosing cohort, patients received IV ME-143 on days 1, 2, 8,
9, 15, 16, and were evaluated on day 22 with 1 week of rest
(cycle 1). In subsequent cycles, ME-143 was administered
on 2 consecutive days weekly (days 1, 2, 8, 9, 15, 16, 22,
and 23). Treatment continued until progression or unaccept-
able toxicity and no intra-patient escalation was permitted.
Each treatment cohort was designed to enroll 3–6 patients.
Following a 3+3 design [7], a decision to enroll patients at the
next dose level was made once the last evaluable patient
completed one cycle of ME-143 at their allocated dose level.
Toxicities were graded using National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (CTCAE ver-
sion 4.03) [8]. DLTs were defined as any of the following
during cycle 1: grade ≥3 neutropenia for ≥5 days; febrile
neutropenia; grade 4 thrombocytopenia or grade 3 thrombo-
cytopenia with bleeding; any grade ≥3 abnormal lab values
assessed as clinically significant; any grade ≥3 non-laboratory
toxicity (excluding rash, nausea, diarrhea, and vomiting if
controlled by standard supportive therapy). Once the MTD
was established, the protocol allowed an option to expand this
cohort with the enrollment of an additional three to six addi-
tional patients.
Assessments
Patients underwent physical examinations with assessment
of vital signs and ECOG performance status at screening,
and weekly thereafter. Electrocardiograms (ECGs) were
done in triplicate at screening, with single ECG measure-
ments immediately post-dose on day 1 of each cycle (day 2
of each cycle twice-weekly dosing cohort). Complete blood
counts, including differential and platelet count, and chem-
istry profiles were evaluated at baseline, days 1 and 15 of
each cycle and at end of study. Urinalysis was performed at
baseline, day 1 of each cycle, and end of study. FSH and
testosterone (for women and men, respectively) were
assessed at baseline and end of study. Patients were assessed
for response to treatment, using the Response Evaluation
Criteria in Solid tumors (RECIST 1.1) [9], at least every
12 weeks. Baseline radiology assessments were performed
within 28 days (4 weeks) prior to the first dose of ME-143.
Pharmacokinetics
Blood samples for pharmacokinetic evaluation were collect-
ed during cycle 1 on days 1 and 15 at the following time
points: pre-dose, just prior to the end of infusion, and
10 min, 20 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h
and 24 h post-dose. On the twice-weekly dosing cohort
samples were collected at the same time points and on days
2 and 16 pre-dose and just prior to the end of infusion.
Statistical analysis
This study tested no formal hypotheses, and all analyses
were descriptive and exploratory.
Peak concentrations (Cmax) and trough levels (Cmin)
were determined by inspection of each individual’s
concentration-time curves. Terminal half-lives (t 1/2)
were calculated by dividing 0.693 by the elimination
rate constants. The area under the concentration-time
curve (AUC) was calculated using the linear trapezoidal
rule up to the last measurable time point (AUC0-24),
then extrapolated to infinity (AUC=AUC0-24+Clast/K).
Systemic clearance (CL) was determined by dividing
the dose by AUC. The apparent volume of distribution
at steady-state (Vdss) was determined by the following
relationship: Vdss=(Dose X AUMC/AUC2) – (Dose x
Duration of Infusion/ (2 x AUC), where AUMC is the
area under the moment curve extrapolated to infinity.
Results
Patient characteristics
Between September 2011 and August 2012, eighteen
patients received at least one infusion of ME-143 (Table 1).
The majority of the patients had an ECOG performance status
of 0 (12 patients, 67 %), and colorectal cancer was the most
common tumor type (8 patients, 44 %). Nine patients (50 %)
had received 4 or more prior chemotherapy regimens.
Dose escalation and safety
No DLTs were observed in the once weekly cohorts of 2.
5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg (Table 2). With
no DLTs, the MTD was not exceeded and 20 mg/kg was the
maximally administered dose. Three patients were enrolled
in the twice-weekly cohort. One of the patients enrolled in
this cohort had a grade 4 infusion reaction.
Safety
Treatment-emergent adverse events in ≥10 % of patients are
summarized by dose level in Table 3. The most frequently
reported adverse events irrespective of relationship to ME-
143 across all dose levels were fatigue (33 %), diarrhea
(22 %), and nausea (22 %). Only seven patients experienced
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adverse events deemed related to treatment with ME-143
and with the exception of the grade 4 infusion reaction
described below, these were all grade 1 or 2. There were
no clinically significant changes in testosterone or FSH
levels. Three patients experienced serious adverse events
determined to be unrelated to ME-143 treatment; one patient
with grade 3 paroxysmal supraventricular tachycardia
(20 mg/kg weekly) and two patients with grade 3 pneumo-
nia (both 2.5 mg/kg).
The only adverse events that required treatment discon-
tinuation were the two patients who experienced infusion
reactions related to ME-143. One patient experienced a
grade 2 infusion reaction during her first 20 mg/kg twice-
weekly treatment with ME-143. During the first infusion,
the patient developed a headache and nausea; symptoms
resolved following infusion interruption, and the patient
was able to complete the dose without recurrence. On day
2, the patient’s infusion was interrupted due to the develop-
ment of chest pressure, headache, nausea, and flushing, but
was eventually completed.
A second patient experienced a grade 4 infusion
reaction during her 8th weekly treatment with ME-143.
All previous treatments had been well-tolerated. Within
2 min of the cycle 3 day 1 infusion she developed
severe dyspnea, flushing, and agitation, which progressed to
cardiopulmonary arrest despite halting the infusion. The
patient was successfully resuscitated and discharged
from hospital after a full recovery. Both patients who
experienced infusion reactions discontinued treatment
with ME-143 and were never rechallenged.
Efficacy
Seventeen (94 %) patients were evaluable for efficacy. There
was no complete or partial responses documented. Three
patients had stable disease evident at the first disease evalua-
tion(colorectal cancer (5 mg/kg), anal cancer (20 mg/kg week-
ly), cholangiocarcinoma, (20 mg/kg weekly)); however, these
patients had all discontinued treatment prior to the second
scheduled disease assessment. Fourteen patients had disease
progression at their first assessment.
Pharmacokinetics
Pharmacokinetic parameters for each patient were deter-
mined and the mean values (±SD) for each cohort
Table 1 Patient characteristics (N=18)
Characteristic Number of Patients (%)
Median age, years (range) 65 (20–82)
Sex – female 13 (72 %)
Race – Caucasian 16 (89 %)
Baseline ECOG performance status
0 12 (67 %)
1 6 (33 %)
Primary tumor type
colorectal 8 (44 %)
endometrial 3 (17 %)
cholangiocarcinoma 2 (11 %)
othera 5 (28 %)
Number of prior chemotherapy regimens
1 1 (6 %)
2 or 3 8 (44 %)
4 or more 9 (50 %)
Prior surgery 3 (17 %)
Prior radiation 3 (17 %)
a One patient each: small-cell lung, pancreas, sarcoma, squamous car-
cinoma of the anus, squamous carcinoma of the head and neck











Number of DLTs 0 0 0 0 0
Maximum treatment cycles completed
1 0 0 0 0 1 (33 %)
2 3 (100 %) 2 (67 %) 3 (100 %) 5 (83 %) 1 (33 %)
3 0 0 0 1 (17 %) 0
4 0 1 (33 %) 0 0 1 (33 %)
Patients requiring dose reduction due
to adverse event
0 0 0 0 0
Number of doses held due to adverse event 2 (67 %) 0 0 0 0
Number of patients with infusions interrupted
due to infusion reaction
0 0 0 1 (17 %) 1 (33 %)
Discontinued treatment due to infusion
reaction
0 0 0 1 (17 %) 1 (33 %)
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summarized in Table 4. Samples from 15 patients were
available for PK analysis. PK sample sets were incomplete
for three patients, due to missing or hemolyzed samples.
The population mean half-lives for the weekly dosing co-
horts on Days 1 and 15 were 5.36 (±1.23) hours and 5.10
(±1.31) hours, respectively. Cmax was observed at the end of
the 30 min infusion and increased with increasing dose.
Mean Cmax values achieved at the highest dose level
(20 mg/kg) were 40.13 μg/mL (120 μM) and 37.48 μg/mL
(112 μM) on days 1 and 15, respectively. The inter-patient
variability (CV %) for Cmax at the 20 mg/kg dose level was
45 % on day 1 and 38 % for day 15.
ME-143 exposures (AUC) increased in a dose-proportional
manner (Fig. 1). There was no statistical difference between
dose (mg/kg) and AUC normalized to dose. The inter-patient-
variability for the AUC on days 1 and 15 (17 % and 30 %,
respectively) was relatively low. The population average for
Vdss was 161 (± 81.75) L on Day 1 and 138 (± 56.23) L on
Day 15. Both clearance (P=0.236) and volume of distribution
(P=0.360) values were independent of dose (mg/kg) by the













Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4
Fatigue 3 (100 %) 0 1 (33 %) 0 0 0 2 (33 %) 0 0 0 6 (33 %)
Diarrhea 2 (67 %) 0 1 (33 %) 0 0 0 0 0 1 (33 %) 0 4 (22 %)
Nausea 1 (33 %) 0 1 (33 %) 0 0 0 1 (17 %) 0 1 (33 %) 0 4 (22 %)
Dyspnea 1 (33 %) 0 1 (33 %) 0 1 (33 %) 0 0 1 (17 %) 0 0 4 (22 %)
Headache 1 (33 %) 0 1 (33 %) 0 0 0 0 0 1 (33 %) 0 3 (17 %)
Anemia 0 0 1 (33 %) 0 0 0 1 (17 %) 0 0 0 2 (11 %)
Anxiety 1 (33 %) 0 0 0 0 0 1 (17 %) 0 0 0 2 (11 %)
Back pain 0 0 0 0 1 (33 %) 0 1 (17 %) 0 0 0 2 (11 %)
Constipation 1 (33 %) 0 0 0 0 0 0 0 1 (33 %) 0 2 (11 %)
Cough 2 (67 %) 0 0 0 0 0 0 0 0 0 2 (11 %)
Decreased
appetite
1 (33 %) 0 1 (33 %) 0 0 0 0 0 0 0 2 (11 %)
Dysuria 0 0 0 0 0 0 1 (17 %) 0 1 (33 %) 0 2 (11 %)
Fall 0 0 0 0 1 (33 %) 0 0 0 1 (33 %) 0 2 (11 %)
Hyperglycemia 0 0 1 (33 %) 0 0 0 0 0 1 (33 %) 0 2 (11 %)
Infusion reaction 0 0 0 0 0 0 0 1 (17 %) 1 (33 %) 0 2 (11 %)
Pneumonia 0 2 (67 %) 0 0 0 0 0 0 0 0 2 (11 %)
Productive cough 0 0 0 0 1 (33 %) 0 1 (17 %) 0 0 0 2 (11 %)
Vomiting 1 (33 %) 0 0 0 0 0 0 0 1 (33 %) 0 2 (11 %)
Table 4 Mean (SD) pharmacokinetic parameters of ME-143, weekly schedule
Dose Cmax (μg/mL) Cmin (ng/mL) t1/2 (hr) AUC (μg*hr/mL) CL (L/hr) Vdss (L)
Day 1
2.5 mg/kg 2.18 (1.21) 4.02 (1.89) 4.12* (0.55) 2.96 (0.56) 69.73 (17.2) 230 (105)
5 mg/kg 8.62 (0.32) 34.43 (2.89) 6.95* (0.70) 10.27 (1.16) 37.30 (10.8) 145 (37.1)
10 mg/kg 10.77 (2.31) 16.2 (8.97) 5.54* (1.04) 10.42 (1.20) 58.96 (1.74) 167 (19.8)
20 mg/kg 40.13 (18.2) 37.52 (27.99) 5.47* (1.05) 30.15 (5.11) 60.42 (25.2) 132 (90.7)
Day 15
2.5 mg/kg 3.55 (1.09) 6.12 (4.57) 4.36* (0.92) 3.57 (0.31) 56.18 (3.75) 177 (40.5)
5 mg/kg 8.94 (6.29) 15.93 (4.43) 5.12* (0.85) 9.47 (3.58) 41.32 (7.33) 121 (28.6)
10 mg/kg 17.61 (6.93) 11.83 (5.62) 4.89* (0.66) 12.62 (3.93) 59.41 (22.08) 114 (58.5)
20 mg/kg 37.48 (14.4) 43.21 (27.74) 5.64* (2.21) 29.61 (8.88) 61.43 (20.9) 141 (71.1)
*Harmonic mean
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non-parametric Kruskal-Wallis ANOVA. There was no statis-
tical difference between clearance and volume of distribution
values on days 1 and 15. The clearance and volume of distri-
bution values for patients receiving 20 mg/kg twice-weekly
dosing approximated those observed in patients receiving
20 mg/kg weekly (data not shown).
Discussion
Weekly administration of ME-143 was generally well-
tolerated in this first-in-human study of patients with refrac-
tory solid tumors. There were no dose-limiting toxicities ob-
served, and while there was no formal MTD defined, the
maximally administered dose was 20 mg/kg weekly. Follow-
ing the life threatening infusion reaction during cycle 3 of a
patient receiving 20 mg/kg biweekly, coupled with concurrent
preclinical studies that demonstrated no incremental efficacy
improvements with biweekly dosing, the decision was made
to cease further enrollment to the biweekly cohort. The most
common adverse events related to ME-143 across all dose
levels were fatigue and nausea, all grade 1 or 2.
While ME-143 was well-tolerated by most patients, two
patients experienced infusion reactions to ME-143. The
exact cause of these infusion reactions is not clear; however,
it may be related to the high osmolarity of the final solution
for drug administration. Depending on the degree of dilution
prior to administration, the ME-143 drug product can result
in hyperosmolar infusion solutions, particularly in large
patients (by weight) receiving the highest administered dose
level (20 mg/kg). The two patients with infusion reactions
had delivered osmolarities of 0.67 and 0.74 Osm/L. The
intravenous delivery of hyperosmolar solutions has well
described risk for basophilic histamine release and clinical
anaphylactic-like infusion reactions [10]. Following the ob-
servance of these infusion reactions, ME-143 administration
instructions were modified, by protocol amendment, to keep
the osmolarity of the infusion limited to 0.5 Osm/L. No
further infusion reactions were noted, although few infu-
sions were administered under these revised instructions.
Future studies will need to monitor this adverse event close-
ly as ME-143 moves further in development.
Pharmacokinetic analysis revealed that ME-143 plasma
concentrations decline in a multi-exponential fashion with a
harmonic mean half-life of approximately 5 h. A linear
relationship was observed between ME-143 dose (mg/kg)
and Cmax levels and exposure (AUC) levels on days 1 and
15. Volume of distribution and clearance values were inde-
pendent of ME-143 dose and there were no statistical dif-
ferences in these parameters between days 1 and 15.
Unfortunately, a suitable clinical biomarker has not been
identified to help confirm the adequacy of the exposures
observed at the 20 mg/kg weekly dose.
There were no objective responses to ME-143 documented
in this study. Three patients with gastrointestinal cancers, two
of whom were receiving 20 mg/kg weekly, had stable disease
evident at the first disease assessment but progressed prior to
the second disease assessment. However, in vitro studies with
ME-143 demonstrated synergistic activity with various chemo-
therapy agents (carboplatin, cisplatin, gemcitabine, paclitaxel,
doxorubicin, dacarbazine) in a variety of cancer cell lines
(ovarian, prostate, colorectal, melanoma, glioma, lung, breast,
and pancreas). This in vitro interaction has also been confirmed
in in vivo xenograft models [MEI Pharma, Inc, data on file].
Based on the promising signal observed with IV phenoxodiol
in ovarian cancer, further phase II development of ME-143 will
be conducted in combination with cytotoxic chemotherapy.
In conclusion, ME-143 was reasonably well-tolerated
when administered on a once weekly schedule. With no
dose limiting toxicities, the maximally administered dose
of 20 mg/kg once weekly is the dose recommended for
further study. Though this is the recommended phase II dose
as defined by the protocol, the design of future studies will
need to include careful guidelines for monitoring and man-
agement of infusion reactions, and to confirm that the mod-
ified ME-143 administration instructions ameliorate this
adverse event. Pharmacokinetic exposures at this dose dem-
onstrated that drug levels achieved target concentrations
determined from preclinical studies to be efficacious. Al-
though minimal clinical activity was observed, it is likely
that inhibitors of tNOX such as ME-143 will derive their
greatest benefit in combination.
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